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Abstract
 
Secretory leukoprotease inhibitor (SLPI) protects tissue against the destructive action of neu-
trophil elastase at the site of inflammation. Recent studies on new functions of SLPI have dem-
onstrated that SLPI may play a larger role in innate immunity than merely as a protease inhibi-
tor. To clarify the functions of SLPI in bacterial infections, we generated SLPI-deficient mice
(SLPI
 
 
 
/
 
 
 
 mice) and analyzed their response to experimental endotoxin shock induced by li-
popolysaccharide (LPS). SLPI
 
 
 
/
 
 
 
 mice showed a higher mortality from endotoxin shock than
did wild type mice. This may be explained in part by our observation that SLPI
 
 
 
/
 
 
 
 macro-
phages show higher interleukin 6 and high-mobility group (HMG)-1 production and nuclear
factor 
 
 
 
B activities after LPS treatment than do SLPI
 
 
 
/
 
 
 
 macrophages. SLPI also affects B cell
function. SLPI
 
 
 
/
 
 
 
 B cells show more proliferation and IgM production after LPS treatment
than SLPI
 
 
 
/
 
 
 
 B cells. Our results suggest that SLPI attenuates excessive inflammatory responses
and thus assures balanced functioning of innate immunity.
Key words: endotoxin shock • innate immunity • LPS • NF-
 
 
 
B • SLPI
 
Introduction
 
Bacterial infection can evokes endotoxin shock characterized
by fever, myocardial dysfunction, acute respiratory failure,
and multiple organ failure, resulting in a high mortality rate.
LPS, a major component of the outer membrane of Gram-
negative bacteria, is one of the major toxins that initiate the
cascade of pathophysiological reactions called endotoxin
shock. In the bloodstream LPS is carried by the serum pro-
tein LPS-binding protein (LBP). On the surface of neutro-
phils, monocytes, lymphocytes, and macrophages (1, 2), LPS
binds to CD14 and Toll-like receptor 4 (TLR4),
 
*
 
 triggering
the production of inflammatory cytokines and bioactive
molecules which include TNF-
 
 
 
, IL-1 and IL-6, proteases,
and NO (1, 2). Excessive production of cytokines is consid-
ered to be crucial to the initiation of the endotoxic shock
cascade (1, 2). Neutrophil elastase and cathepsin G–deficient
mice have been shown to be resistant to LPS-induced en-
dotoxin shock (3), thus demonstrating that both cytokines
and proteases define the susceptibility to endotoxin shock.
Secretory leukoprotease inhibitor (SLPI) is an 11.7 kD
(107 amino acid), nonglycosylated, single-chain serine pro-
tease inhibitor (4). SLPI is produced by secretory cells in re-
spiratory, genital and lacrimal glands, and by inflammatory
cells that include macrophages, neutrophils, and B cells (5–
8). SLPI inhibits several serine proteases. Examples are
elastase and cathepsin G secreted from neutrophils, trypsin
and chymotyrpsin from pancreatic acinar cells, and chymase
and tryptase from mast cells (4). Therefore, a major physio-
logical role of SLPI is considered to be the protection of
tissue from these proteases at sites of inflammation (4).
However, recent studies have demonstrated that SLPI func-
tions as more than just a protease inhibitor. SLPI suppresses
bacterial growth (9), inhibits infection of lymphocytes by
human immunodeficiency virus-I (HIV-Ip; reference 10),
ameliorates bacterial arthritis (11), and decreases production
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Abbreviations used in this paper:
 
 CLP, cecal ligation and puncture; ES,
embryonic stem; HMG, high-mobility group; SLPI, secretory leukopro-
tease inhibitor; TLR, Toll-like receptor.T
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of prostaglandin (PG)E2 and matrix metalloproteinases
(MMP)-1 and 9 (12). SLPI is involved in normal cutaneous
wound healing, a result previously shown in a study on
SLPI
 
 
 
/
 
 
 
 mice (13, 14). Moreover, SLPI modifies macro-
phage functions in mice, as shown by the fact that ectopic
expression of SLPI cDNA in macrophages increases their re-
sistance to LPS, and that SLPI suppresses macrophage response
to LPS (7). Consistently, serum SLPI levels are elevated in en-
dotoxin shock in human (15). These observations strongly
suggest that SLPI is an important participant in innate immu-
nity where it acts as an antiinflammatory molecule.
To clarify the function of SLPI in innate immunity, we
generated a mouse strain lacking SLPI by gene targeting in
embryonic stem cells and analyzed their response to exper-
imental endotoxic shock induced by LPS. As expected,
SLPI
 
 
 
/
 
 
 
 mice were highly sensitive to LPS or cecal ligation
and puncture (CLP)-induced sepsis compared with SLPI
 
 
 
/
 
 
 
mice. Macrophages lacking SLPI were also highly respon-
sive to LPS with increased IL-6 and HMG (high-mobility
group)-1 production and nuclear factor (NF)-
 
 
 
B activa-
tion. These results indicated that endogenous SLPI inhib-
ited the signaling pathways though LPS-CD14:TLR4 re-
sulting in the protective function upon septic shock.
 
Materials and Methods
 
Generation of SLPI
 
 
 
/
 
 
 
 Mice.
 
The SLPI genomic DNA was
isolated from the 129/Sv mouse genomic library constructed into
lambda Fix II (Stratagene). The insert was subcloned into pBlue-
script SK(-) vector (Stratagene), and confirmed by restriction en-
zyme mapping and DNA sequencing. A targeting vector was de-
signed to replace all four exons of the SLPI gene with a PGK
promoter driven NEO (neomycin resistance gene) expression
cassette. The targeting vector was electroporated into E14.1 em-
bryonic stem (ES) cells and selected with G418. Homologous re-
combinants were identified by Southern hybridization using a ge-
nomic probe located on the 3
 
 
 
 side of the SLPI gene: Southern
hybridization detected a 5.0 kb StuI fragment of the endogenous
SLPI allele and a 4.0 kb fragment of the targeted allele. The iden-
tified targeted ES clones were microinjected into the blastocysts
of C57BL/6 mice. Chimeric mice were crossed with C57BL/6
females to generate heterozygous mice. Heterozygous mice were
intercrossed to obtain homozygous mice. SLPI
 
 
 
/
 
 
 
 mice and their
wild-type (SLPI
 
 
 
/
 
 
 
) littermates were used in this study. These
mice were kept and bred in the Animal Unit of The Institute of
Development, Aging and Cancer, a facility which is environmen-
tally controlled and specific pathogen-free.
 
Southern Blot Analysis and PCR Genotyping.
 
For Southern
blot analysis, DNA was isolated from G418-resistant ES cells or
from mouse liver and digested with StuI. Hybridization was per-
formed with 
 
32
 
P (Amersham Biosciences)-radiolabeled 5
 
 
 
 or 3
 
 
 
probes indicated in the figure. For PCR genotyping, DNA was
isolated from mouse-tail biopsies. PCR primers used were
p38F1 (forward: 5
 
 
 
-CATGTGAACACTTCAGAAGAGAAGG-3
 
 
 
)
and PGKR1 (reverse: 5
 
 
 
-GCTACTTCCATTTGTCACGTC-
CTGC-3
 
 
 
) to detect the knockout allele, or p38F1 and SLPIR1
(reverse: 5
 
 
 
-GTGAGATGCTGAGAACTAAAGCCAG-3
 
 
 
) to
detect the wild-type allele. Amplification was performed using
rTth DNA polymerase (PerkinElmer) by 40 cycles of 40 s at
94
 
 
 
C, 30 s at 55
 
 
 
C, and 4 min at 68
 
 
 
C. For RT-PCR, total
RNA was isolated from macrophages by RNeasy Mini Kit
(QIAGEN). Primers used were forward 5
 
 
 
-ATGAAGTCCT-
GCGGCCTTTT-3
 
 
 
 and reverse 5
 
 
 
-GCATAGAGAAATGAA-
TGCGT-3
 
 
 
 for SLPI, and forward 5
 
 
 
-CTACAATGAGCT-
GCGTGTGG-3
 
 
 
 and reverse 5
 
 
 
-AGGAAGGCTGAAGAG-
TGC-3
 
 
 
 for 
 
 
 
-actin. Amplification was performed by OneStep
RT-PCR kit (QIAGEN).
 
Induction of LPS-induced Endotoxin Shock.
 
10- to 12-wk-old
SLPI
 
 
 
/
 
 
 
 mice and wild-type littermates (body weight 20–23 g)
were intraperitoneally injected with 1.0 mg or 0.5 mg of LPS
from 
 
Escherichia coli
 
 serotype 0127:B8 (Sigma-Aldrich). The mice
were injected at time 0 and monitored for survival for 5 d. Serum
concentrations of IL-6, TNF-
 
 
 
, and IL-1
 
 
 
 were measured by
ELISA (Endogen).
 
Induction of Cecal Ligation and Puncture.
 
The CLP was used as
a model of systemic sepsis syndrome as described previously (16).
Briefly, mice were anesthetized with ketamine hydrochloride
(100 mg/kg, intraperitoneally) and xylazine hydrochloride (10
mg/kg, intraperitoneally), and a 1- to 2-cm longitudinal incision
was performed to the middle of the abdomen. After the cecum
was exposed, its distal one-third point was ligated with a 4–0 silk
suture, and its proximal part was punctured twice with a 26-gauge
needle. The cecum was then returned into the peritoneal cavity,
and the incision was closed by suturing peritoneum and fascia sep-
arately with a 4–0 prolene suture to prevent leakage of fluid. The
mice were monitored for survival for 5 d.
 
Preparation of Peritoneal Macrophages and LPS Treatment.
 
Mice
were intraperitoneally injected with 2 ml of 4% thioglycollate
medium (Sigma-Aldrich). Peritoneal cells were isolated by wash-
ing the peritoneal cavity with ice-cold PBS. The cells were cul-
tured for 1 h and nonadherent cells were washed out by PBS. Ad-
herent cells (peritoneal macrophages: 5 
 
  
 
10
 
6
 
) were cultured with
LPS (100 ng/ml; Sigma-Aldrich) or LPS and IFN-
 
 
 
 (100 U/ml,
PeproTech) in DMEM medium (Sigma-Aldrich) with 10% fetal
bovine serum (GIBCO BRL) for 12 or 24 h. Concentrations of
IL-6, IL-1
 
 
 
, and TNF-
 
 
 
 in the culture supernatants were mea-
sured by ELISA (Endogen). Production of NO
 
2
 
 
 
 was measured
by Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical).
 
B Cell Proliferation Assay.
 
CD19-positive splenic B cells were
purified by MACS magnetic cell sorter (Miltenyi Biotec). Puri-
fied B cells (3 
 
  
 
10
 
5
 
) were cultured with the indicated con-
centration of LPS for 24 h. Cells were pulsed with 0.5 Bq of [
 
3
 
H]
thymidine (Amersham Biosciences) for the last 8 h. The incorpo-
rated radioactivity was measured by a 
 
 
 
 scintillation counter.
Concentration of IgM in the culture supernatants was measured
by ELISA (BETHYL INC.).
 
Western Blot Analysis and Electrophoretic Mobility Shift Assay.
 
The whole cell protein from peritoneal macrophages (5 
 
  
 
10
 
6
 
)
was prepared by M-PER Mammalian Protein Extraction Reagent
(Pierce Chemical Co.) with protease inhibitor cocktail (Sigma-
Aldrich). Protein concentration was determined by BCA Protein
Assay Reagent (Pierce Chemical Co.). Whole cell protein or cell
culture medium was denatured by boiling in SDS-PAGE sample
buffer, separated on SDS-PAGE and transferred onto a nitrocellu-
lose membrane. The membrane was treated with antibodies
against mouse SLPI, I
 
 
 
B-
 
 
 
, I
 
 
 
B-
 
 
 
, or HMG-1 (Santa Cruz Bio-
technology, Inc.) and the specific bands were detected by BCIP/
NBT Phosphatase Substrate System (Kirkegaard & Perry Labs).
Electrophoretic mobility shift assay (EMSA) was performed using
the Gel Shift Assay System (Promega). Briefly, double-stranded
NF-
 
 
 
B (Promega) and C/EBP-
 
 
 
 (Santa Cruz Biotechnology,
Inc.) consensus oligonucleotides (5 
 
 
 
g each) were end-labeled
with [
 
  
 
32
 
P]ATP (Amersham Biosciences). Whole cell protein
(5 
 
 
 
g) and oligonucleotide were incubated in binding buffer forT
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20 min. Reaction products were separated in a Novex 6% TBE
Gel (Invitrogen) and detected by autoradiography.
 
Results and Discussion
 
Generation of SLPI-deficient Mice.
 
To investigate the
function of endogenous SLPI in bacterial infection, and
thus to clarify the role of SLPI in innate immunity, we
have generated a mouse strain lacking SLPI by gene tar-
geting in ES cells. We disrupted the mouse SLPI gene by
replacing all four exons with a PGK-NEO expression cas-
sette (Fig. 1 A). The targeting vector was electroporated
into ES cells and G418-resistant colonies were isolated.
Correctly targeted ES cells were injected into C57BL/6
blastocysts and chimeric mice were generated. The chi-
meric mice transmitted the mutated allele through the
germline, which enables generation of heterozygous mice
and homozygous mice by intercrosses. We confirmed the
absence of SLPI gene loci by both Southern blot analysis
(Fig. 1 B) and RT-PCR (Fig. 1 C). The SLPI
 
 
 
/
 
 
 
 mice
reproduced normally and appeared healthy without any
obvious abnormalities.
Figure 1. (A-C) Disruption of the SLPI gene by homologous recombi-
nation. (A) Structure of the SLPI genomic loci (i), the targeting construct
(ii), and the SLPI loci after homologous recombination (iii). (B) Southern
blot analysis. Genomic DNA was isolated from mouse liver, digested with
StuI and hybridized with a probe located on the 5  side of the SLPI gene.
(C) SLPI expression in the peritoneal macrophages detected by RT-PCR.
Figure 2. (A) Mortality after
LPS administration. Age-matched
SLPI /  mice ( , n   21) and
SLPI /  mice ( , n   21) were
intraperitoneally injected with
LPS (1 mg/mouse). Mortality was
assessed every 12 h for 5 d. The
experiment was repeated three
times and mean values are shown.
Statistical analyses were per-
formed using Fisher’s exact test:
**P     0.01 between SLPI / 
mice and SLPI /  mice. (B)
Dose–response curves of mortal-
ity in SLPI /  mice ( , n   10–
21) and SLPI /  mice ( , n  
10–21). The experiment was re-
peated three times and the results
are presented as mean   SD. Sta-
tistical analyses were performed
using Fisher’s exact test: *P   
0.05, **P   0.01 between SLPI / 
mice and SLPI /  mice. (C–E)
Serum concentration of cytokines
in SLPI /  mice after LPS injec-
tion. SLPI /  mice ( , n   6)
and SLPI /  mice ( , n   6) were
intraperitoneally injected with
LPS (1 mg/ml). Samples were
taken at 2, 6, and 24 h after LPS
administration. IL-6 (C), IL-1  (D), and TNF-  (E) concentrations were determined by ELISA. These analyses are representative of three separate experi-
ments. Results are presented as mean   SD. Statistical analyses were performed using Student’s t test: **P   0.01 between SLPI /  mice and SLPI /  mice.
Table I. Survival Rate (%) of the Mice in LPS or
CLP-induced Sepsis
SLPI /  SLPI / 
LPS (0.5 mg/mouse) 80% (12/14) 67% (10/15)
LPS (1 mg/mouse) 80% (17/21) 24% (5/21)
CLP 86% (12/14) 43% (6/14)
Mice were injected intraperitoneally with LPS (0.5 mg or 1 mg/mouse)
or received CLP. Mice were observed for 5 d.T
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SLPI  /  Mice Are Highly Sensitive to LPS-induced Endo-
toxin Shock. SLPI /  mice were subjected to the study of
experimental endotoxin shock induced by LPS. SLPI / 
mice and SLPI /  mice were intraperitoneally injected
with LPS (1 mg/mouse), and their survival was then moni-
tored. After the LPS challenge, many of the SLPI    mice
survived, whereas 76% of the SLPI    mice died (Fig. 2 A,
Table I). Similar results were obtained in the experiments
using lower doses (Fig. 2 B, Table I). Both SLPI    and
SLPI    mice showed a remarkable increase in the serum
levels of inflammatory cytokines, IL-6, IL-1 , and TNF- 
(Fig. 2, C–E). SLPI /  mice, however, showed a signifi-
cantly higher level of IL-6 than wild-type mice at 6 h (Fig.
2 C), suggesting that this may be the cause of the high
mortality in SLPI /  mice after LPS treatment.
Increased Susceptibility to CLP-induced Sepsis in SLPI / 
Mice. SLPI /  mice were subjected to an in vivo model
of sepsis, CLP, in which bacterial peritonitis is induced by
surgical perforation of the cecum. As expected, SLPI / 
mice showed a significantly higher lethality than SLPI / 
mice (Fig. 3, Table I). These results conform to the idea
that SLPI has a regulatory role against endotoxin shock in-
duced by gram-negative bacteria.
Response to LPS in Macrophages and B Cells of SLPI / 
Mice. The macrophage plays a critical role in the process
of endotoxin shock (17). In mammalians, macrophages are
the primary responders to LPS and they release numerous
bioactive molecules such as inflammatory cytokines, H2O2
and NO. To examine the effect of SLPI deficiency on
macrophages, thioglycollate-elicited peritoneal macro-
phages were stimulated with LPS (100 ng/ml) for 12 or
Figure 3. Survival curves after receiving the CLP procedure. Mortality
in the age-matched SLPI /  mice ( , n   14) and SLPI /  mice ( ,
n   14) were observed every 12 h for 5 d.
Figure 4. (A-D) LPS-induced production of
cytokines and NO2  from SLPI /  and SLPI / 
macrophages. Thioglycollate-elicited perito-
neal macrophages from SLPI /  mice ( ) and
SLPI /  mice ( ) were cultured with LPS (100
ng/ml) for 12 or 24 h. Concentrations of IL-6
(A), IL-1  (B), TNF-  (C), and NO2
  (D) in
the supernatants were measured by ELISA. (E
and F) Proliferation and IgM production of
SLPI /  B cells in response to LPS. Splenic B
cells from SLPI /  mice ( ) and SLPI /  mice
( ) were purified and cultured with the indi-
cated concentrations of LPS for 24 h. (E) Cells
were pulsed with 0.5 Bq of [3H] thymidine for
the last 8 h. The incorporated radioactivity was
measured by a   scintillation counter. (F) Con-
centrations of IgM in the culture supernatants
were measured by ELISA. All analyses are rep-
resentative of five separate experiments. Results
are presented as mean   SD. N.D., not de-
tected. Statistical analyses were performed using
Student’s t test: *P   0.01 between SLPI / 
mice and SLPI /  mice.T
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24 h, after which the supernatants were harvested and ana-
lyzed. Consistent with the in vivo results, macrophages
from SLPI /  mice produced significantly more IL-6 than
SLPI /  mice (Fig. 4, A–D). Moreover, macrophages from
SLPI    mice showed higher levels of HMG-1, which is a
late mediator of endotoxin lethality (18), than SLPI   
mice (Fig. 5), showing that endogenous SLPI plays a criti-
cal role in LPS-induced IL-6 and HMG-1 production.
In response to LPS, B cells secrete SLPI and at the same
time begin to proliferate and to produce immunoglobulins.
To evaluate the SLPI action on the activation of B cells,
splenic B cells were cultured in the presence of different
concentrations of LPS. B cells from mice lacking SLPI
showed a stronger proliferative response to LPS than did B
cells from their wild-type littermates (Fig. 4 E). In addition,
B cells from SLPI /  mice produced more IgM than those
from SLPI /  mice (Fig. 4 F). These results indicate that
SLPI inhibits the activation of B cells. On the other hand,
the proliferative response of B cells upon B cell receptor
(BCR) stimulation showed no differences between SLPI / 
and SLPI /  mice (data not shown).
Inhibitory Effects on LPS Signaling Pathways by SLPI.
Recently, TLR4 was identified as a macrophage receptor
for LPS (19). After associating with CD14, TLR4 recog-
nizes LPS and binds to it. TLR4 then activates various sig-
naling molecules involving MyD88, IL-1R–associated ki-
nase (IRAK), TRAF6, and I kinase (I K), leading to the
degradation of I B. After the degradation of I B, NF- B
enters the nucleus and then exerts its action (1, 2). This
pathway is regulated at multiple points, e.g., TLR4 on the
cell surface of macrophage is down-regulated after LPS
treatment (20). Data showing that recombinant SLPI di-
rectly interferes with the LPS–CD14 complex formation
(21) and that overexpression of SLPI in macrophages sup-
presses LPS-induced NF- B activation (22) provide evi-
dence that SLPI affects this pathway. The inhibitory ef-
fects of SLPI on LPS signaling, however, are still
controversial because administration of recombinant SLPI
has no effect on macrophage responsiveness to LPS (22).
To investigate the role of SLPI on the signaling pathway,
we first examined the surface expression of TLR4 and
CD14. Macrophages from SLPI /  mice (SLPI /  mac-
rophages) and from wild-type mice (SLPI /  macro-
phages) were cultured with LPS for 24 h and analyzed by
flow cytometry. Contrary to the previous report (21),
SLPI /  macrophages had no effect on CD14 or TLR4
expression (data not shown).
In the signaling pathway, SLPI /  macrophages and
wild-type macrophages showed similar levels of I B-  ex-
pression during LPS treatment (Fig. 6 A). I B-  expression
in SLPI / macrophages remained suppressed at both 30
and 60 min, while that in SLPI /  macrophages was re-
stored at 60 min (Fig. 6 A). DNA binding activity of NF-
 B in SLPI /  macrophages was stronger than that in
SLPI /  macrophages during LPS stimulation, especially at
60 and 120 min (Fig. 6 B). Moreover, C/EBP-  activation
of SLPI /  macrophages was also higher than that of
SLPI /  macrophages at 120 min (Fig. 6 B). These results
indicate that SLPI suppresses the activation of NF- B as
well as C/EBP- , which is, at least in part, mediated by the
regulation of the I B-  level, and also suggest that the in-
creased IL-6 production in SLPI /  mice depends upon
Figure 5. LPS-induced production of HMG-1 from SLPI /  and
SLPI /  macrophages. Peritoneal macrophages from SLPI /  and SLPI / 
mice were stimulated with LPS (100 ng/ml) for the indicated periods.
HMG-1 protein in the culture medium was detected by Western blot
analysis. The results are representative of three separate experiments.
Figure 6. (A) Changes in the expression of mouse SLPI, I B- , and  
in response to LPS in macrophages from SLPI /  and SLPI /  mice.
Peritoneal macrophages from SLPI /  and SLPI /  mice were stimulated
with LPS (100 ng/ml) for the indicated periods. Western blot analysis was
performed for SLPI (top panel), I B-  (middle) and   (bottom). (B) NF-
 B and C/EBP-  activities in response to LPS in macrophages from
SLPI /  and SLPI /  mice. The whole cell lysate (5  g protein) from ei-
ther SLPI /  or SLPI /  was incubated with a specific NF- B or C/EBP- 
probe, and NF- B (top) and C/EBP-  (bottom) activity was determined
by the electrophoretic mobility shift assay (EMSA). The results are repre-
sentative of three separate experiments.T
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the elevation of the activities of both NF- B and C/EBP- .
In support of our observation, administration of recom-
binant SLPI inhibited LPS-induced I B-  and   degrada-
tion (23).
In conclusion, our present study for the first time pro-
vides evidence that SLPI /  mice are highly sensitive to
LPS or CLP, and demonstrates that SLPI inhibits the LPS
signaling pathway through suppression of NF- B and acti-
vation of C/EBP- . SLPI counteracts excessive inflamma-
tory responses and thus assures the adequate functioning of
innate immunity.
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